Sitagliptin and Ertugliflozin

Therapeutic indications

Sitagliptin and Ertugliflozin is indicated for:

Diabetes mellitus type 2

Population group: only adults (18 years old or older)

Ertugliflozin/sitagliptin combination is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise:

to improve glycaemic control when metformin and/or a sulphonylurea (SU) and one of the monocomponents of ertugliflozin/sitagliptin do not provide adequate glycaemic control.
in patients already being treated with the combination of ertugliflozin and sitagliptin as separate tablets.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

5 mg of ertugliflozin and 100 mg of sitagliptin once daily

Contraindications

Sitagliptin and Ertugliflozin is contraindicated in the following cases:

Pregnancy

Lactation

Patients with eGFR <45 mL/min/1.73 m²

at least one of

Renal failure stage 5: Kidney failure (GFR <15 mL/min/1.73 m2 or dialysis)

Diabetes mellitus type 1

Diabetes mellitus type I

Diabetic ketoacidosis

Major surgical procedures, acute serious medical illnesses

at least one of

Surgical procedure
Infectious disease

< Previous: Overview

Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.